Asia Healthcare Holdings appoints three new Independent Directors to the board

IMT News Desk
IMT News Desk
· 3 min read
Asia Healthcare Holdings (AHH), backed by GIC and TPG, has appointed Murali Sivaraman, Vinita Bali and Rashmi Joshi as Independent Directors

GIC & TPG-led Asia Healthcare Holdings (AHH) has announced the appointment of three new Independent Directors to its Board.

The newly constituted Board includes seasoned industry veterans Mr Murali Sivaraman, Ms Vinita Bali and Ms Rashmi Joshi, who have joined as Independent Directors effective 1st May, 2026. The Board will also constitute Ms Cynthia Lau, Mr Mayank Rawat & Mr Lav Agarwal from GIC, Mr Ankur Thadani and Mr Bhushan Bopardikar from TPG Growth, in addition to Mr Vishal Bali, Executive Director.

Mr Murali Sivaraman will be Non-Executive Independent Director & Board Chairperson. Murali is an accomplished business leader with over three decades of global experience spanning consumer, industrial and healthcare sectors. He has held leadership positions at Royal Philips and Imperial Chemical Industries (ICI), driving large-scale business transformation, growth, and international expansion across Asia, Europe, and North America.

Ms Vinita Bali will be Non-Executive Independent Director & NRC Chairperson. Vinita is a seasoned global business leader and an accomplished CEO, having worked across business domains and geographies. She has four decades of global experience in senior leadership roles at leading multinational organisations, including The Coca-Cola Company and Cadbury Schweppes. She also served as the Managing Director & CEO of Britannia Industries in India. Her experience also includes Independent Director roles at Companies & Foundations in India and overseas.

Ms Rashmi Joshi will be Non-Executive Independent Director & Audit Committee Chairperson. Rashmi is a distinguished corporate finance leader with over three decades of experience across Finance, Strategy & transformation in global organisations across sectors including FMCG, pharmaceuticals, and energy. Across an 18-year stint in BP/Castrol, she played multiple roles in the finance function globally, including CFO and Whole Time Director of Castrol India operation. Her last role was Group CFO at Veedol Corporation.

Welcoming the Directors to the Board, Mr. Vishal Bali, Executive Director, said, We are delighted to welcome our esteemed Independent Directors to Asia Healthcare Holdings at an important phase of our growth journey. AHH has recently completed 10-years in building and shaping single-speciality healthcare delivery in India. The Board’s extensive leadership experience, coupled with deep expertise in corporate strategy, governance, and financial leadership, will be invaluable as we continue to scale AHH in its next phase of growth. We look forward to their collective guidance”.

AHH today operates three single-speciality enterprises, Motherhood Hospitals, Nova IVF Fertility, and Asian Institute of Nephrology and Urology, with a collective strength of 150+ hospitals and clinics. The portfolio companies have a deep presence in 80+ cities across India and are backed by over 2,000 doctors and 6,100+ employees, delivering specialised care at scale.

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk